Table 1.
Patient characteristics
| PATIENT CHARACTERISTICS | ALL WARFARIN USERS (N = 13 481) | THOSE WITH AF (N = 5010) | THOSE WITH VTE (N = 730) |
|---|---|---|---|
| Female sex, n (%) | 6285 (46.6) | 2221 (44.3) | 379 (51.9) |
| Mean (SD) age, y | 71.9 (14.0) | 75.1 (11.3) | 63.1 (15.9) |
| Mean (SD) BMI, kg/m2 | 30.1 (6.8) | 30.2 (6.5) | 31.8 (7.3) |
| Mean (SD) GFR, mL/min | 64.7 (19.9) | 58.2 (16.7) | 56.3 (17.7) |
| Comorbidities, n (%) | |||
| • Hypertension | 8103 (60.1) | 3349 (66.9) | 370 (50.7) |
| • Osteoarthritis | 4852 (36.0) | 2149 (42.9) | 288 (39.5) |
| • Diabetes | 4144 (30.7) | 1670 (33.3) | 178 (24.4) |
| • Depression | 3075 (22.8) | 1061 (21.2) | 233 (31.9) |
| • COPD | 2747 (20.4) | 1146 (22.9) | 125 (17.1) |
| • Dementia | 1770 (13.1) | 731 (14.6) | 62 (8.5) |
| Warfarin-related condition, n (%) | |||
| • AF | 5010 (37.2) | 5010 (100.0) | 184 (25.2) |
| • DVT | 621 (4.6) | 160 (3.2) | 621 (85.1) |
| • PE | 131 (1.0) | 33 (0.7) | 131 (18.0) |
| Medications, n (%) | |||
| • ≥ 4 medications (including warfarin) | 7120 (52.8) | 2807 (56.0) | 292 (40.0) |
| • Cardiovascular drugs | 9973 (74.0) | 4179 (83.4) | 340 (46.6) |
| • Lipid-modifying drugs | 5779 (42.9) | 2187 (43.7) | 179 (24.5) |
| • Drugs for acid disorders | 4323 (32.1) | 1707 (34.1) | 202 (27.7) |
| • Drugs for COPD or asthma | 3085 (22.9) | 1213 (24.2) | 134 (18.4) |
| • Antidepressants | 2961 (22.0) | 1029 (20.5) | 186 (25.5) |
| • Thyroid-related drugs | 1975 (14.7) | 799 (16.0) | 73 (10.0) |
| • Antiepileptics | 1743 (12.9) | 660 (13.2) | 125 (17.1) |
| • Anxiolytics | 1510 (11.2) | 510 (10.2) | 62 (8.5) |
| • ASA | 967 (7.2) | 499 (10.0) | 39 (5.3) |
| • Other antiplatelets | 457 (3.4) | 165 (3.3) | 10 (1.4) |
| • Psycholeptics | 576 (4.3) | 196 (3.9) | 46 (6.3) |
| • Anti-dementia drugs | 381 (2.8) | 132 (2.6) | 5 (0.7) |
AF—atrial fibrillation, ASA—acetylsalicylic acid, BMI—body mass index, COPD—chronic obstructive pulmonary disease, DVT—deep vein thrombosis, GFR—glomerular filtration rate, PE—pulmonary embolism, VTE—venous thromboembolism.